Analysts have slightly raised their price target for LivaNova, increasing it from $69.00 to $69.10. This change reflects incremental improvements in profit margin and discount rate assumptions.
What's in the News
- LivaNova PLC announced that the U.S. Centers for Medicare & Medicaid Services will significantly increase reimbursement rates for VNS Therapy procedures starting January 1, 2026. Hospital outpatient payments will rise by approximately 48% for new patient implants and 47% for end-of-service procedures (Key Developments).
- These CMS changes are expected to improve hospital economics, broaden access to VNS Therapy for patients with drug-resistant epilepsy and focal seizures, and reduce barriers to adoption by covering more of the procedure costs (Key Developments).
- The recently completed CORE-VNS study showed that patients experienced a median seizure reduction at 36 months of 80% for focal onset motor seizures with impaired awareness, and 95% for focal to bilateral tonic-clonic seizures (Key Developments).
- LivaNova PLC raised its 2025 full-year earnings guidance, increasing the outlook for organic revenue growth by 50 basis points to between 9.5% and 10.5% (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from $69.00 to $69.10.
- Discount Rate has fallen modestly from 8.56% to 8.52%.
- Revenue Growth projections have decreased marginally from 6.91% to 6.88%.
- Net Profit Margin is up slightly, moving from 10.37% to 10.41%.
- Future P/E ratio has edged lower, from 28.41x to 28.34x.
Have other thoughts on LivaNova?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.